Berberine: a review of its pharmacokinetics properties and therapeutic potentials in diverse vascular diseases
R.VerganiN.Galdieri LdeC.Ribeiro PortoM
9.Tian G, Sawashita J, Kubo H, Nishio SY, Hashimoto S, Suzuki N, Yoshimura H, Tsuruoka M, Wang Y, Liu Y, Luo H, Xu Z, Mori M, Kitano M, Hosoe K, Takeda T, Usami S, Higuchi K
Department of Medicine, University Medical Centre Mainz, Johannes Gutenberg University, Mainz, Germany, Mainz, Germany Background: Fib-4 was developed as a non-invasive biomarker to predict advanced fibrosis in other liver disease and was consequently adopted in nonalcoholic fatty liver disease (NAFLD) / nonalcoholic steatohepatitis (NASH) by international guidelines
This prompted the further examination of DSePA as a lung radiomitigator to prevent radiation-induced pneumonitis (RP)